Deerfield Management Company L.P. Series C Has $538,000 Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Deerfield Management Company L.P. Series C boosted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 9.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,942 shares of the company’s stock after purchasing an additional 757 shares during the period. Deerfield Management Company L.P. Series C’s holdings in RxSight were worth $538,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RXST. CWM LLC lifted its holdings in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares during the last quarter. Quest Partners LLC bought a new position in RxSight during the second quarter valued at approximately $41,000. Larson Financial Group LLC acquired a new stake in RxSight in the first quarter valued at approximately $51,000. Amalgamated Bank grew its position in RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of RxSight during the 2nd quarter worth $156,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Stock Down 0.7 %

Shares of NASDAQ RXST opened at $48.54 on Friday. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54. The company has a market cap of $1.80 billion, a P/E ratio of -38.52 and a beta of 1.22. The business’s 50 day moving average is $51.15 and its two-hundred day moving average is $53.82.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million during the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business’s quarterly revenue was up 67.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.40) EPS. Sell-side analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Insider Activity at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,225,096.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at $816,906.18. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,225,096.82. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,200 shares of company stock worth $1,267,516. Company insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company reduced their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, BTIG Research increased their price target on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.